Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety ...

Selling CagriSema, if approved ... Hsieh added that the result may prove Zepbound’s mechanism of action — stimulating the gut hormones GLP-1 and GIP — yields better results.

The pharmaceutical industry is not stopping there. There are already 100 new drug candidates in trials, all vying for a slice ...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

Its experimental candidates, amycretin and CagriSema, aim to improve weight loss outcomes through a dual mechanism. However, recent disappointing trial results for CagriSema have weighed on Novo ...